In 2020, Isobe et al. paired the NIR photosensitizer IR700 with the anti-DLL3 monoclonal antibody Rovalzumab to create rova-IR700 (Figure 12a) for targeted NIR photo immunotherapy (NIR-PIT) of SCLC [76]. Here, DLL3 is linked to small cell lung carcinoma.